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AbstrAct
Introduction Surgical resection is the only curative 
treatment for patients with resectable pancreatic cancer. 
Unfortunately, 80%–85% of patients present with locally 
advanced or metastatic unresectable pancreatic cancer 
at the time of diagnosis. Detection of pancreatic cancer 
at early stages remains a great challenge due to lack of 
accurate detection tests. Recommendations in existing 
clinical practice guidelines on early diagnosis of pancreatic 
cancer are inconsistent and based on limited evidence. 
Most of them endorse measuring serum  
CA19-9 as a complementary test, but also state that it is 
not recommended for diagnosing early pancreatic cancer. 
There are currently no other tumour-specific markers 
recommended for diagnosing early pancreatic cancer. 
This study aims to evaluate and compare the accuracy 
of five common tumour biomarkers (CA242,carcino-
embryonic antigen (CEA)), CA125, microRNAs and K-ras 
gene mutation) and CA19-9 and their combinations for 
diagnosing pancreatic cancer using network meta-analysis 
method, and to rank these tests using a superiority index.
Methods and analysis PubMed, EMBASE and the 
Cochrane Central Register of Controlled Trials will be 
searched from inception to April 2017. The search will 
include the above-mentioned tumour biomarkers for 
diagnosing pancreatic cancer, including CA19-9. The risk 
of bias for each study will be independently assessed as 
low, moderate or high using criteria adapted from the 
Quality Assessment of Diagnostic Accuracy Studies 2. 
Network meta-analysis will be performed using STATA 
V.12.0 and R software V.3.4.1. The competing diagnostic 
tests will be ranked by a superiority index.
Ethics and dissemination Ethical approval and patient 
consent are not required since this study is a network 
meta-analysis based on published studies. The results of 
this network meta-analysis will be submitted to a  
peer-reviewed journal for publication.
PrOsPErO registration number CRD42017064627.
IntrOductIOn
Pancreatic cancer is the fourth leading cause 
of cancer death in the USA.1 The American 
Cancer Society estimates that there will be 
53 670 newly diagnosed pancreatic cancers 
in the USA in 2017, and that 43 090 will die 
from the disease.1 Despite decades of effort 
in detection and management of pancreatic 
cancer, the 5-year survival rate is only about 
4%.2 The number of patients with pancre-
atic cancer is currently increasing year by 
year and is predicted to become the second 
leading cause of cancer death in the USA by 
2030.3 
Systemic chemotherapy has been demon-
strated to prolong survival in patients with 
resectable or metastatic pancreatic cancer,4–6 
although surgical resection is the only cura-
tive treatment.2 Unfortunately, 80%–85% 
of patients present with locally advanced or 
metastatic unresectable pancreatic cancer at 
the time of diagnosis.2 Detection of pancreatic 
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Protocol
strengths and limitations of this study
 ► To the best of our knowledge, this will be the first 
diagnostic network meta-analysis comparing 
different tumour biomarkers combined with or 
without CA19-9 for pancreatic cancer.
 ► Current network meta-analysis will compare 
simultaneously the accuracy of multiple tests within 
and between studies and rank the diagnostic tests 
using a superiority index.
 ► Our results of this network meta-analysis will 
help clinicians and patients to select appropriate 
diagnostic test for pancreatic cancer.
 ► Our results will be limited by both the quantity and 
quality of the studies available for review.
 ► Our subgroup analyses of network meta-analysis 
will be based on the reporting of baseline 
characteristics of included original studies; some 
expected characteristics of patients may not be 
reported adequately.
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cancer at early stages remains a great challenge due to 
lack of specific detection tests.7
Many investigations have been conducted to find the 
appropriate serum and imaging biomarkers to help 
early detection of pancreatic cancer.8 Currently, several 
biomarkers (such as carcinoembryonic antigen, CA19-9, 
CA125, microRNAs, etc) have been proposed for pancre-
atic cancer detection, although the clinical applicability 
of these tests remains unclear.9 The recommendations in 
existing clinical practice guidelines on early diagnosis of 
pancreatic cancer are inconsistent and based on limited 
evidence.10 Most of them endorse measuring serum 
CA19-9 as a complementary test, but also stated that it is 
not useful for diagnosing early pancreatic cancer or for 
screening.10 There are currently no other tumour-specific 
markers recommended for diagnosing early pancreatic 
cancer.10
Tumour markers, imaging approaches or combina-
tion of the two might be the future of pancreatic cancer 
screening.11 A combination of serum CA19-9 and CEA has 
been reported to increase specificity to 84% compared 
with CA19-9 alone, and CA19-9 combined with CA125 
improved sensitivity.12 Meta-analyses have also shown 
that the combined tests of CA19-9 plus CA242, or CA19-9 
plus K-ras gene mutation or endoscopic retrograde 
cholangiopancreatography plus endoscopic ultrasonog-
raphy could be of better diagnostic value than individual 
tests.13–16 Moreover, a combination of microRNAs and 
CA19-9 was more accurate, especially in early pancreatic 
cancer screening.17 18 However, it is still unclear which 
individual test or combined test is the best for diagnosing 
pancreatic cancer based on currently available studies.
Network meta-analysis has been used to extend conven-
tional meta-analyses on multiple treatments (ie, three 
or more) for a given condition.19 An attractive feature 
of network meta-analysis is the ranking of interventions 
using rank probabilities and rankograms. Similarly, there 
are often multiple candidate tests for diagnosing a partic-
ular disease outcome in a diagnostic test accuracy study.20 
In order to present an overall picture, network meta-anal-
ysis (mainly refers to indirect comparison) has been 
proposed by some researchers to simultaneously compare 
the accuracy of multiple tests within and between studies 
and rank the diagnostic tests using diagnostic OR (DOR) 
and a superiority index.20–26
This study aims to evaluate and compare the accu-
racy of five common tumour biomarkers (CA242, CEA, 
CA125, microRNAs and K-ras gene mutation) and CA19-9 
and their combinations for diagnosing pancreatic cancer 
using network meta-analysis method, and to rank these 
tests using superiority index.
MEthOds
design and registration
We will conduct a network meta-analysis of diagnostic 
test accuracy. We have registered the protocol on the 
international prospective register of systematic review 
(PROSPERO).27 We will follow the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses28 state-
ments for reporting our systematic review.
Information sources
PubMed, EMBASE and the Cochrane Central Register of 
Controlled Trials will be searched from inception to April 
2017. The search strategies will be developed by GL and 
TJH who are experienced information specialists. The 
references of relevant systematic reviews/meta-analyses 
will be searched to identify additional potential studies.
search strategy
The search terms will include: pancreatic neoplasm, 
pancreas neoplasms, pancreas neoplasm, pancreas 
cancers, pancreas cancer, pancreatic cancer, pancreatic 
cancers, CA199, carbohydrate antigen 199, sensitivity 
and specificity. Full details of the search strategies can be 
found in online supplementary appendix 1.
Eligibility criteria
Eligibility criteria are as follows: (1) index tests include 
either CA19-9, CA242, CEA, CA125, microRNAs and 
K-ras gene mutation, or combinations thereof; (2) at least 
two index tests per study, one of them being CA19-9; (3) 
report or provide sufficient information to allow us to 
calculate the true positive (TP), false positive (FP), true 
negative (TN) and false negative (FN) values; (4) case–
control, cross-sectional or cohort designs; there will be no 
limitations on language of publication, year of publica-
tion, publication status or stage of pancreatic cancer.
study selection and data extraction
Initial search records will be imported into ENDNOTE 
X6 literature management software, then the titles and 
abstracts of records will be screened to identify poten-
tial trials according to eligibility criteria. Next, full-text 
versions of all potentially relevant trials will be obtained 
and reviewed to ensure eligibility.
A standard data extraction form will be created using 
Microsoft Excel 2013 (Microsoft, Redmond, Washington, 
USA, www. microsoft. com) to collect data of interest, 
which include eligible studies characteristics (eg, name 
of first author, year of publication, country in which the 
study was conducted, gold standard, index tests), patients 
characteristics (male, mean age, sample, method, cut-off 
level, risk factors of pancreatic cancer) and outcomes 
(TP, FP, FN, TN).
Study selection and data extraction will be performed by 
one reviewer (LG), and will be checked by other reviewers 
(BP, JT). Any conflicts will be resolved by discussion.
Quality evaluation
Two reviewers will independently assess the risk of bias for 
each study as low, moderate or high using criteria adapted 
from Quality Assessment of Diagnostic Accuracy Studies 
2,29 and conflicts will be resolved by discussion.
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Geometry of the network
We will draw network plots using R software V.3.4.1. In 
network plots, the size of the nodes is proportional to the 
number of studies evaluating a test, and thickness of the 
lines between the nodes is proportional to the number 
of direct comparisons between tests. The network is 
connected because there exists at least one study evalu-
ating a given test together with at least one of the other 
remaining tests.20 A loop connecting three tests indi-




We will perform pairwise meta-analyses for pooled sensi-
tivity (SEN), specificity (SPE), positive likelihood ratio, 
negative likelihood ratio, DOR and area under the 
summary receiver operating characteristic curve using 
bivariate mixed-effects regression modelling with STATA 
V.12.0 (Stata). The between-study variance will be calcu-
lated var logitSEN and logitSPE.30 31 The proportion of 
heterogeneity due to the threshold effect among the 
included studies will be calculated by the squared correla-
tion coefficient estimated from the between-study covari-
ance variable in the bivariate model.32 The heterogeneity 
between each study will be estimated using the Q value 
and the inconsistency index (I2 test, and the values of 25%, 
50% and 75% for the I2 will be indicative of low, moderate 
and high statistical heterogeneity, respectively.33
Subgroup analyses for each biomarker will be planned 
on the basis of the country in which the study was 
conducted, stage of pancreatic cancer, cut-off level, risk 
factors of pancreatic cancer and risk of bias.
The Deek’s funnel plot will be applied to evaluate the 
potential publication bias where there are more than 10 
studies available for an index test.34
Indirect comparisons between competing diagnostic tests
Using CA19-9 as common reference test, we will calculate 
relative diagnostic outcomes between index tests by anal-
ysis of variance model in R software V.3.4.1,20 including 
relative SEN, relative SPE and relative DOR.
Ranking of competing diagnostic tests
Ranking of interventions is an attractive feature of network 
meta-analysis. Currently, it is still challenging to rank 
competing diagnostic tests. Some researchers consider 
DOR as a indicator of ranking of competing diagnostic 
tests25; however, the measure cannot distinguish between 
tests with high sensitivity but low specificity or vice versa. 
Alternatively, the superiority index introduced by Deutsch 
et al26 gives more weight to tests performing relatively well 
on both diagnostic accuracy measures and less weight on 
tests performing poorly on both diagnostic measures or 
tests performing better on one measure but poorly on the 
other.20 The superiority index ranges from 0 to ∞, and 
tends towards ∞ and 0 as the number of tests to which the 
target test is superior and inferior increases, respectively, 
and the superiority index tending to one indicates that 
the tests are equal.20
EthIcs And dIssEMInAtIOn
Ethical issues
Ethical approval and patient consent are not required 
since this is a network meta-analysis based on published 
studies.
Publication plan
This protocol has been registered on the international 
prospective register of systematic review (PROSPERO).27 
The results of this network meta-analysis will be submitted 
to a peer-reviewed journal for publication.
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